Ara-290
← Back to LibraryCompound Profile
Ara-290 is reviewed here for cognition, mood, and brain-health context.
Research Summary
Human studies, published literature, supporting research
Cognition, Mood, Brain health
Target context: Innate Repair Receptor
Human data exists, but longer-term context is still developing.
Human research exists, but confidence depends on product, dose, and population.
Route(s)
Subcutaneous
Typical dose
4mg
Dosing window
Anytime
Receptor / target
Innate Repair Receptor
Properties
Not listed
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 4mg daily | Consistent daily dosing required for continuous nerve regeneration. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 2 mg 1x Daily | Initiation phase. |
| Weeks 2-12 | 4 mg 1x Daily | 12 weeks on, 6 week washout. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 8 mg 1x Daily | Aggressive protocol. Maximum 4 weeks. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied in neuroprotection, cognition, anxiety, sleep, stroke, neuropathy, or neuropeptide models depending on the target and route. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Innate Repair Receptor. Route(s): Subcutaneous. Dosing window on page: Anytime. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- ARA-290/cibinetide was studied as an erythropoietin-derived tissue-protective peptide with neuropathy and inflammatory-pain endpoints in human and translational literature.
- The main evidence gap is that clinical programs explored narrow disease states and did not establish general wellness or repair protocols.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-4, 4mg daily; Alternative Titration 1: Week 1, 2 mg 1x Daily.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor sleep, anxiety or mood activation, blood pressure, seizure history, psychiatric history, and route-specific nasal or injection irritation.
Selected medical sources
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Known hypersensitivity to ARA-290, EPO-derived peptides, or formulation excipients.
- Active malignancy with EPO receptor expression: while ARA-290 does not drive erythropoiesis, certain tumors express IRR components (βcR) and could theoretically receive pro-survival IRR signaling; caution in oncological contexts.
- Concurrent full-dose EPO administration: ARA-290 and EPO may compete at the EPOR/βcR receptor complex; combined use is not characterized.
- Pregnancy: IRR signaling in fetal tissue development is not characterized; safety not established.
- Breastfeeding: no safety data.
- Pediatric use: no safety or dosing data established.
- Autoimmune conditions currently treated with immunosuppressive biologics: ARA-290's immunomodulatory activity may interact unpredictably with concurrent biologic immunosuppression.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Mild injection site irritation: the most consistently reported adverse effect; localized redness, mild tenderness, and minor swelling at the subcutaneous injection site; mild and self-resolving; standard for subcutaneous peptide administration.
- Mild transient fatigue: reported in a subset of subjects during the first week; possibly related to the acute neuroinflammatory modulation phase.
- Mild headache: uncommon; transient; mechanism not characterized.
- Transient dizziness: rare; mild; possibly related to βcR-mediated vasodilatory activity in some subjects.
- Nausea: uncommon; mild; self-limiting.
- No erythropoietic effects: ARA-290 has no meaningful activity at the classical EPOR homodimer that drives red blood cell production; hematocrit and hemoglobin are not elevated; there is no thrombotic or polycythemia risk.
- No hormonal disruption: ARA-290 has no activity at endocrine receptors; does not affect the HPA axis, sex hormones, thyroid, or IGF-1 axis.
- Potential IRR desensitization with continuous long-term use: not documented but theoretically possible with extended uninterrupted administration; the washout protocol mitigates this.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.